Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre,…
By A. Sartore-Bianchi, Livio Trusolino, C. Martino, K. Bencardino, S. Lonardi, F. Bergamo, V. Zagonel, F. Leone, I. Depetris, E. Martinelli and 20 more. The Lancet Oncology, 2016
867 citations recorded by the source corpus.
Subfields: Oncology
View Paper: https://www.semanticscholar.org/paper/902d0b938fec74e846b6e114a899720dcadb2ead
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020, background): “As mentioned before, TRK inhibitors showed high efficacy in multihistology trials in NTRK fusion-positive tumours(50,85); and mCRC with ERBB2 amplifications/overexpression (detected with FISH or IHC) presented significant responses with dual HER2 therapy in prospective studies.(86,87) In Table 5 we ”